Patents by Inventor Tatsuo Eto

Tatsuo Eto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treatment of Hepatitis C virus-associated diseases
    Patent number: 6423489
    Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 23, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furusako, Thomas W. Bruice, Walter F. Lima
  • Compositions and methods for treatment of Hepatitis C virus-associated diseases
    Patent number: 6391542
    Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: May 21, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furasako, Thomas W. Bruice, Walter F. Lima
  • Compositions and methods for treatment of hepatitis C virus-associated diseases
    Patent number: 6284458
    Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: September 4, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa
  • Recombinant plasmid inserted with herpes simplex virus gene
    Patent number: 5059538
    Abstract: A novel recombinant plasmid inserted with a herpes simplex virus gene, which comprises a plasmid vector containing a yeast DNA sequence and an Escherichia coli DNA sequence and carrying a promoter region and a herpes simplex virus gN gene (HSVgB) gene) recombined thereto under control of the promoter, said HSVgB gene lacking an N-terminal portion of the gene including a signal sequence-encoding region and optionally further lacking the region downstream therefrom, such as a gB gene lacking a DNA sequence encoding the N-terminal 30 amino acids, and a gB gene lacking a DNA sequence encoding the N-terminal 83 amino acids. The recombinant plasmid is useful for the production of transformed yeast, which is useful for the production of HSVgB proteins suitable for producing HSV vaccine and diagnostic reagents for herpes simplex virus infections.
    Type: Grant
    Filed: August 15, 1986
    Date of Patent: October 22, 1991
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Chikateru Nozaki, Hiroshi Nakatake, Yoichiro Kino, Tatsuo Eto, Keiichi Makizumi, Nobuya Ohtomo